Harvard Bioscience, Inc. announced its financial results for Q4 and the full year 2025, reporting revenues of $23.7M for Q4 and $86.6M for the year. The company also appointed Mark Frost as permanent CFO and provided guidance for 2026, anticipating revenue growth driven by new products.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.